Oral contraceptive use and the ECG: Evidence of an adverse QT effect on corrected QT interval

Annals of Noninvasive Electrocardiology

Volumn 18, Issue 4, 2013, Pages 389-398

  Sedlak, Tara ^a   Shufelt, Chrisandra ^a   Iribarren, Carlos ^b   Lyon, Liisa L ^b   Bairey Merz, C Noel ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b DIVISION OF RESEARCH   (United States)

Author keywords

hormones; QT

Indexed keywords

ANTIANDROGEN; CONTRACEPTIVE AGENT; ESTROGEN; GESTAGEN;

ADOLESCENT; ADULT; ARTICLE; COMORBIDITY; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; ORAL CONTRACEPTIVE USE; PREMENOPAUSE; PRIORITY JOURNAL; QT INTERVAL;

HORMONES; QT;

ADOLESCENT; ADULT; AGE FACTORS; ANALYSIS OF VARIANCE; CALIFORNIA; CONTRACEPTIVES, ORAL; CROSS-SECTIONAL STUDIES; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84880823037     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/anec.12050     Document Type: Article

References (22)

1. Algra A, Tijssen JG, Roelandt JR, et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991; 83: 1888-1894.
2. Kadish AH, Greenland P, Limacher MC, et al. Estrogen and progestin use and the QT interval in postmenopausal women. Ann Noninvasive Electrocardiol 2004; 9: 366-374.
3. Carnethon MR, Anthony MS, Cascio WE, et al. A prospective evaluation of the risk of QT prolongation with hormone replacement therapy: The atherosclerosis risk in communities study. Ann Epidemiol 2003; 13: 530-536.
4. Nakagawa M, Ooie T, Takahashi N, et al. Influence of menstrual cycle on QT interval dynamics. Pacing Clin Electrophysiol 2006; 29: 607-613.
5. Rodriguez I, Kilborn MJ, Liu XK, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322-1326.
6. Saito T, Ciobotaru A, Bopassa JC, et al. Estrogen contributes to gender differences in mouse ventricular repolarization. Circ Res 2009; 105: 343-352.
7. Zhang Y, Ouyang P, Post WS, et al. Sex-steroid hormones and electrocardiographic QT-interval duration: Findings from the third national health and nutrition examination survey and the multi-ethnic study of atherosclerosis. Am J Epidemiol 2011; 174: 403-411.
8. Krieger N,. Overcoming the absence of socioeconomic data in medical records: Validation and application of a census-based methodology. Am J Public Health 1992; 82: 703-710.
9. Kligfield P, Hancock EW, Helfenbein ED, et al. Relation of QT interval measurements to evolving automated algorithms from different manufacturers of electrocardiographs. Am J Cardiol 2006; 98: 88-92.
10. Indik JH, Pearson EC, Fried K, et al. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 2006; 3: 1003-1007.
11. Malik M, Farbom P, Batchvarov V, et al. Relation between QT and RR intervals is highly individual among healthy subjects: Implications for heart rate correction of the QT interval. Heart 2002; 87: 220-228.
12. van Noord C, Dorr M, Sturkenboom MC, et al. The association of serum testosterone levels and ventricular repolarization. Eur J Epidemiol 2010; 25: 21-28.
13. Larsen JA, Tung RH, Sadananda R, et al. Effects of hormone replacement therapy on QT interval. Am J Cardiol 1998; 82: 993-995.
14. Interdisciplinary review team for QT studies. 2010;2012.
15. Laliberte F, Dea K, Duh MS, et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011; 18: 1052-1059.
16. Lacut K, Oger E, Le Gal G, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on c-reactive protein. Thromb Haemost 2003; 90: 124-131.
17. Zegura B, Guzic-Salobir B, Sebestjen M, et al. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006; 13: 643-650.
18. Brosnan JF, Sheppard BL, Norris LA,. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: Less effect with transdermal administration ? Thromb Haemost 2007; 97: 558-565.
19. Nowinski K, Pripp U, Carlstrom K, et al. Repolarization measures and their relation to sex hormones in postmenopausal women with cardiovascular disease receiving hormone replacement therapy. Am J Cardiol 2002; 90: 1050-1055.
20. Noseworthy PA, Havulinna AS, Porthan K, et al. Common genetic variants, QT interval, and sudden cardiac death in a finnish population-based study. Circ Cardiovasc Genet 2011; 4: 305-311.
21. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006; 47: 362-367.
22. Extramiana F, Maison-Blanche P, Cabanis MJ, et al. Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther 2005; 77: 247-258.